Biogen Snaps Up Apellis For $5.6 Billion, Adding Two New Drugs To Its Portfolio

Biogen (BIIB) is bulking up its non-neurology profile with the $5.6 billion takeover of Apellis Pharmaceuticals (APLS). But Biogen stock slipped Tuesday following the announcement while Apellis shares soared. Adam Keeney, Biogen’s executive vice president and head of corporate development, says it will probably take some time for analysts to wrap their heads around the story. Apellis sells Syfovre, a…